Pharmaceuticals

Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers

BEIJING and PHILADELPHIA, Jan. 24, 2022 /PRNewswire/ -- Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been a...

2022-01-24 13:10 3710

Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, sele...

2022-01-23 18:35 5170

Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022

SAN FRANCISCO and SUZHOU, China, Jan. 22, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2022-01-22 08:00 9338

Swiss Pharma Company - IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)

HURDEN, Switzerland, Jan. 22, 2022 /PRNewswire/ -- IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russia, and CIS. BELEODAQ® is a prescription medicine used to treat patients with a rare form of blood canc...

2022-01-22 04:24 5093

Sihuan Pharmaceutical (0460.HK): Establishment of Joint Venture with Bluepha Co., Ltd.

HONG KONG, Jan. 21, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group:" Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce thatBeijing MeiYan KongJian...

2022-01-21 11:12 6608

Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an orally bioavailable Chimeric Degrader targeting Androgen Receptor for Prostate Cancer Treatment

MELBOURNE, Australia, Jan. 21, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, announced that the first patient with metastat...

2022-01-21 05:30 2918

HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update

* 2021 sales of KRW 101.6 billion for a 15% increase from 2020 * 2021 operating profit of KRW 10.1 billion grew by 70% from 2020 * Increasing milestone payments and revenues from R&D activities are reinvested into new R&D programs SEOUL, South Korea, Jan. 20, 2022 /PRNewswire/ -- [Busines...

2022-01-20 22:00 2906

Bridget Johnson Joins CSafe Global as Senior Vice President of Marketing

CSafe Global makes strategic addition to its senior leadership team bringing Bridget Johnson on board as the SVP of Marketing   DAYTON, Ohio, Jan. 20, 2022 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled container solutions for the transport of life-enhancing pharma...

2022-01-20 21:15 6324

Victor Papamoniodis Joins Medison Pharma as VP International Markets

ZUG, Switzerland, Jan. 20, 2022 /PRNewswire/ -- Medison , a global pharma company focused on providing access to highly innovative therapies to patients in international markets ("Medison"), is proud to announce the joining ofVictor Papamoniodis in the newly create...

2022-01-20 20:35 3332

Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment

MELBOURNE, Australia, Jan. 20, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today announced that the first patient with m...

2022-01-20 20:28 2577

Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Des...

2022-01-20 20:00 2954

Sputnik V demonstrates strong protection against Omicron variant, with over 2 times higher virus neutralizing activity compared to the Pfizer vaccine according to a unique independent comparative study conducted by the Spallanzani Institute in Italy

Previous studies also demonstrated additional significant strengthening of protection against Omicron by Sputnik Light booster, which can also be a universal booster to other vaccines to strengthen and lengthen their protection against Omicron. MOSCOW, Jan. 20, 2022 /PRNewswire/ -- * A uniqu...

2022-01-20 19:00 5634

Successful Completion of First Patient Implantation of MINI WELL® and MINI WELL TORIC® Extended Depth-of-Focus IOLs in China Announced by Affamed Technologies, Joint Venture between AffaMed Therapeutics and SIFI

CATANIA, Italy, Jan. 20, 2022 /PRNewswire/ -- SIFI, a leading international ophthalmic company headquartered inItaly, is pleased to divulge the successful completion of the first patient implantation of MINI WELL® and MINI WELL TORIC® IOLs inChina, announced via Affamed Technologies, Joint Ventur...

2022-01-20 16:00 3860

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris (TM) Nasal Spray in Singapore, Hong Kong and Vietnam

* Under the terms of the agreement, Glenmark will be responsible for the manufacture and supply of Ryaltris™, while Lotus International Pte. Ltd. will be responsible for the commercialization of Ryaltris™ (subject to receipt of regulatory approvals) across these markets. * Glenmark will recei...

2022-01-20 15:48 3339

Nippon Express (Belgium) Acquires GDP Certification for Facility in Brussels Airport's Cargo Area

TOKYO, Jan. 20, 2022 /PRNewswire/ -- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a company of the Nippon Express Holdings, Inc. Group, has obtained Good Distribution Practice (GDP) certification, effective December 21, 2021, for air and ground forwarding operations, inclusive of...

2022-01-20 15:00 2205

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fourth consecutive year for the certification inThailand * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 3230

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the third consecutive year for the certification inIndonesia * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 3560

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fourth consecutive year for the certification inPhilippines * High scores in values, ethics and integrity serve as a driver for a strong...

2022-01-20 08:00 2950

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the second consecutive year for the certification inAustralia & New Zealand * High scores in values, ethics and integrity serve as a driver ...

2022-01-20 08:00 2860

Award: Boehringer Ingelheim is Global Top Employer 2022

* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the fourth consecutive year for the certification inMalaysia * High scores in values, ethics and integrity serve as a driver for a strong c...

2022-01-20 08:00 2889
1 ... 305306307308309310311 ... 345